Invented by Gregory Moore, John Desjarlais, Seung Chu, Sung-Hyung Lee, Xencor Inc

The market for trispecific antibodies has been gaining significant attention in recent years. Trispecific antibodies are a type of engineered antibody that can simultaneously target three different antigens, making them highly versatile and potentially more effective than traditional monoclonal antibodies. The demand for trispecific antibodies is primarily driven by the need for more targeted and personalized therapies in the field of oncology. Cancer is a complex disease that often requires a combination of treatments to effectively combat it. Trispecific antibodies offer the potential to target multiple cancer-specific antigens simultaneously, increasing the chances of a successful treatment outcome. Furthermore, trispecific antibodies can also be used to target other diseases beyond cancer. They have shown promise in the treatment of autoimmune disorders, infectious diseases, and even neurodegenerative conditions. This broad applicability has attracted the interest of pharmaceutical companies and researchers alike, leading to a surge in investment and development in this field. One of the key advantages of trispecific antibodies is their ability to engage multiple immune effector cells simultaneously. By binding to different antigens, trispecific antibodies can recruit various immune cells, such as T cells, natural killer cells, and macrophages, to attack the targeted cells. This multi-pronged approach enhances the immune response and can potentially overcome resistance mechanisms that cancer cells often develop. The market for trispecific antibodies is expected to grow significantly in the coming years. According to a report by Grand View Research, the global trispecific antibodies market size was valued at $1.1 billion in 2020 and is projected to reach $5.6 billion by 2028, growing at a compound annual growth rate (CAGR) of 22.7%. This growth can be attributed to the increasing prevalence of cancer and other diseases, as well as the growing interest in personalized medicine. Several pharmaceutical companies and biotechnology firms are actively involved in the development of trispecific antibodies. For instance, Roche, a leading player in the pharmaceutical industry, has developed a trispecific antibody called mosunetuzumab for the treatment of non-Hodgkin lymphoma. Similarly, Amgen has developed a trispecific antibody called AMG 420 for the treatment of multiple myeloma. However, despite the promising potential of trispecific antibodies, there are still challenges to overcome. The development process for trispecific antibodies is complex and requires sophisticated engineering techniques. Additionally, there are regulatory hurdles and manufacturing challenges that need to be addressed to ensure the widespread availability of these therapies. In conclusion, the market for trispecific antibodies is poised for significant growth in the coming years. The ability of trispecific antibodies to target multiple antigens simultaneously makes them a promising tool in the fight against cancer and other diseases. As research and development in this field continue to progress, we can expect to see more innovative therapies and improved patient outcomes.

The Xencor Inc invention works as follows

Provided are trispecific antibody that includes a) first monomer, second monomer and light chain. The first monomer comprises a variant Fc first domain and variable heavy domain. The second monomer comprises a variant Fc second domain and first scFv and the lightchain includes a variant light domain. The variable heavy and light domains form an antigen-binding domain. The trispecific antibodies also include a second scFv on either the second or first monomer.

Background for Trispecific antibodies

I. Definitions

II. “II. Overview of Multispecific Bindings


Heterodimerization Antibodies

Chimeric Antibodies and Humanized Antibodies

Additional Fc Variants

Fc?R Variants

scFv Embodiments

Heterodimeric heavy chain Constant Regions

Heterodimerization Variants

Steric Variants

pI (Isoelectric point) Variants for heterodimers

Heavy Chain pI Changes

Antibody Heterodimers Light Chain Variants

Isotypic Variants

Calculating pI

Combination of Heterodimeric variants

Target Antigens

CD20 Antigen Binding Domains

Nucleic Acids” of the Invention


Click here to view the patent on Google Patents.